142.50
-1.31 (-0.91%)
| Previous Close | 143.81 |
| Open | 143.96 |
| Volume | 3,748,754 |
| Avg. Volume (3M) | 1,464,190 |
| Market Cap | 20,892,579,840 |
| Price / Earnings (TTM) | 13.64 |
| Price / Earnings (Forward) | 9.69 |
| Price / Sales | 2.27 |
| Price / Book | 1.29 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 15.07% |
| Operating Margin (TTM) | 28.05% |
| Diluted EPS (TTM) | 10.12 |
| Quarterly Revenue Growth (YOY) | 6.10% |
| Quarterly Earnings Growth (YOY) | -38.90% |
| Total Debt/Equity (MRQ) | 39.00% |
| Current Ratio (MRQ) | 1.44 |
| Operating Cash Flow (TTM) | 2.58 B |
| Levered Free Cash Flow (TTM) | 3.43 B |
| Return on Assets (TTM) | 5.43% |
| Return on Equity (TTM) | 9.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bullish | Bearish |
| Drug Manufacturers - General (Global) | Bullish | Bearish | |
| Stock | Biogen Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 5.0 |
| Average | 0.63 |
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Value |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 92.79% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 219.00 (RBC Capital, 53.68%) | Buy |
| Median | 169.50 (18.95%) | |
| Low | 118.00 (Piper Sandler, -17.19%) | Hold |
| Average | 167.50 (17.54%) | |
| Total | 3 Buy, 3 Hold | |
| Avg. Price @ Call | 135.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 10 Oct 2025 | 149.00 (4.56%) | Hold | 146.57 |
| 01 Aug 2025 | 144.00 (1.05%) | Hold | 131.95 | |
| Jefferies | 25 Sep 2025 | 190.00 (33.33%) | Buy | 135.67 |
| Piper Sandler | 14 Aug 2025 | 118.00 (-17.19%) | Hold | 134.94 |
| Citigroup | 01 Aug 2025 | 135.00 (-5.26%) | Hold | 131.95 |
| HC Wainwright & Co. | 01 Aug 2025 | 194.00 (36.14%) | Buy | 131.95 |
| RBC Capital | 01 Aug 2025 | 219.00 (53.68%) | Buy | 131.95 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |